Copyright
©The Author(s) 2025.
World J Clin Oncol. Apr 24, 2025; 16(4): 100729
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.100729
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.100729
Table 1 Patient and tumor characteristics
Characteristic | MDTB group (n = 117) | non-MDTB group (n = 276) | P value |
Gender, male/female | 73/44 | 189/87 | 0.651 |
Age, years | 52.7 ± 17.1 | 49.2 ± 15.8 | 0.219 |
Indication for transplantation | |||
Hepatitis B cirrhosis | 84 (71.8) | 208 (75.4) | 0.662 |
Alcoholic cirrhosis | 18 (15.4) | 39 (14.1) | 0.772 |
Other | 15 (12.8) | 29 (10.5) | > 0.990 |
MELD score at transplantation | 17.1 ± 4.7 | 16.5 ± 4.9 | 0.215 |
PreOP biology | |||
Total bilirubin, μmol/L | 79.5 ± 76.9 | 74.7 ± 68.2 | 0.841 |
Serum creatinine, μmol/L | 86.1 ± 72.6 | 82.6 ± 66.3 | 0.377 |
INR | 1.4 ± 0.6 | 1.5 ± 0.6 | 0.447 |
Plasma ammonia, μmol/L | 39.7 ± 21.5 | 42.6 ± 23.4 | 0.669 |
AFP, ng/mL1 | 23.4 (7-194) | 30.1 (7-388) | 0.165 |
PIVKA-II, mAU/mL1 | 39.5 (19-372) | 47.3 (21-463) | 0.312 |
Waiting time for LT | |||
From HCC diagnosis, months | 3.3 ± 2.6 | 2.9 ± 2.5 | 0.153 |
From listing, days | 47.8 ± 51.4 | 44.7 ± 48.8 | 0.571 |
Radiological characteristics | |||
Number of nodules | 2.4 ± 1.3 | 2.3 ± 1.3 | 0.486 |
Size of the largest nodule, mm | 47.9 ± 18.3 | 45.6 ± 17.9 | 0.248 |
Multifocal tumors | 41 (35) | 88 (31.9) | 0.652 |
UCSF criteria | 0.499 | ||
Within UCSF criteria | 68 (58.1) | 171 (61.9) | |
Exceeding UCSF criteria | 49 (41.9) | 105 (38.1) | |
Bridging therapy | 87 (74.4) | 139 (50.4) | 0.021 |
TACE | 65 (55.6) | 86 (31.5) | < 0.001 |
RFA | 11 (9.4) | 28 (10.1) | > 0.990 |
SBRT | 2 (1.7) | 3 (1.1) | 0.637 |
Resection | 4 (3.4) | 8 (2.9) | 0.756 |
Other | 5 (4.3) | 14 (5.1) | > 0.990 |
Pathological characteristics | |||
Poorly (Edmonson grade III/IV) | 56 (47.8) | 129 (46.7) | 0.912 |
(Micro-) vascular invasion | 37 (31.6) | 82 (29.7) | 0.719 |
Capsular invasion | 33 (28.2) | 77 (27.9) | > 0.990 |
- Citation: Zhang L, Yang J, Li JJ, Chen CY, Wang XD, Xie Y, Jiang WT. Multidisciplinary tumor board is associated with improved survival in patients with hepatocellular carcinoma after liver transplantation. World J Clin Oncol 2025; 16(4): 100729
- URL: https://www.wjgnet.com/2218-4333/full/v16/i4/100729.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i4.100729